Vertex Pharmaceuticals (NASDAQ: VRTX) delivered a second quarter strong on execution and bolder on strategy. Revenue of $3.33 billion beat consensus by about $105 million. Non-GAAP EPS of $4.73 landed within a penny of estimates. Management raised full-year revenue guidance for the second consecutive quarter.
But the headline that will define this period is the $10 billion acquisition of Crinetics Pharmaceuticals. The move adds rare endocrine diseases as a fifth therapeutic pillar. It signals that Vertex is willing to deploy its $13.6 billion cash pile for external innovation.
Total revenue increased 12% year-over-year, driven by the CF portfolio and early contributions from CASGEVY ($76 million) and JOURNAVX ($50 million). The CF franchise remains the engine: TRIKAFTA/KAFTRIO contributed $2.50 billion, while ALYFTREK added $574 million, up from $157 million a year ago. The ALYFTREK ramp is accelerating as reimbursement expands. 25 countries now cover it, and a Canadian letter of intent was signed during the quarter.
Non-CF revenue is becoming material. CASGEVY grew 151% year-over-year to $76 million, with sequential growth of 78%. The FDA's recent label expansion to children aged 2 and older unlocks an additional ~5,500 eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. JOURNAVX more than quadrupled year-over-year to $50 million, with roughly 535,000 prescriptions filled in the quarter. Reimbursed access now covers about 260 million lives across commercial and government payers, including three of the four major Medicare Part D PBMs.
The $10 billion Crinetics acquisition is the strategic centerpiece. Vertex is paying $85 per share in cash, a premium that reflects the value of atumelnant, a once-daily oral ACTH antagonist in Phase 3 for congenital adrenal hyperplasia and Cushing's disease. The deal is expected to close in Q3 2026. Vertex will not integrate Crinetics' financials into guidance until after close, but the transaction will consume roughly three-quarters of Vertex's $13.6 billion in cash and marketable securities. That is a large bet on a single pipeline asset, but one that fits Vertex's playbook: rare, genetically defined diseases with clear regulatory pathways.
Operating expenses are rising as Vertex invests behind the non-CF launches and the renal franchise. Combined GAAP R&D, AIPR&D, and SG&A expenses reached $1.6 billion in Q2, up from $1.4 billion a year ago. The increase reflects commercial investment for JOURNAVX and build-out of the povetacicept launch infrastructure in IgA nephropathy. The PDUFA date for povetacicept is November 30, 2026. If approved, it would become Vertex's first commercialized nephrology product and a test case for whether the company can replicate its CF commercial model in a new disease area.
Guidance was raised modestly. Full-year 2026 revenue is now expected at $13.1 billion to $13.2 billion, up from $12.95 billion to $13.1 billion. The non-CF product revenue target of $500 million or more was reiterated. Operating expense guidance was unchanged. The guidance raise is conservative relative to the Q2 beat, suggesting management is leaving room for uncertainty around the pace of ALYFTREK uptake and the trajectory of CASGEVY and JOURNAVX adoption.
The Crinetics acquisition is the real story here, not the in-line print. Vertex is using its balance sheet to buy a fifth pillar rather than build it organically, a departure from its historical preference for internal R&D. The deal carries integration risk and execution risk; atumelnant is still in Phase 3. But it also diversifies Vertex beyond CF and pain into endocrine diseases, a new therapeutic area with high unmet need. Investors will watch the close timeline and the post-close guidance update for signals on how quickly the combined pipeline can deliver.
What to watch next: the povetacicept PDUFA in November, the pace of CASGEVY label expansion uptake in the pediatric population, and whether the Crinetics deal closes on schedule. The Q2 print confirms that Vertex's core CF business is durable and that its non-CF launches are gaining traction. The strategic question is whether the $10 billion bet on Crinetics will prove as transformative as the CF franchise has been.